Moderna Jumps 5% as 1,137-Patient Melanoma Data Looms on October 24

โดย 24/7 Wall St.·

Summary · why it matters

Moderna shares rose another 5% to $181.51 on Tuesday morning, extending a 516% year-to-date gain, as investors position ahead of a late-October readout for the company's personalized cancer therapy. Moderna said detailed Phase 3 results for intismeran autogene, developed with Merck, will be presented at the European Society for Medical Oncology Congress in a Presidential Symposium on October 24. The data come from the INTerpath-001 study, which enrolled 1,137 participants and tested intismeran plus Merck's Keytruda against Keytruda alone in high-risk melanoma patients whose tumors had been surgically removed; Moderna reported last month that the trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, with both companies calling the improvements statistically significant and clinically meaningful, but releasing no underlying numbers. BioNTech, the other large messenger RNA developer, is up just 5% year to date at $100.42, a contrast that suggests the market is pricing an intismeran-specific outcome rather than a broad re-rating of the mRNA platform. Moderna and Merck are running intismeran across nine mid-stage and late-stage studies in other tumor types, including non-small cell lung cancer, bladder cancer and renal cell carcinoma, so the October 24 hazard ratios and survival curves carry binary risk for a stock that has rallied on a top-line conclusion rather than a dataset.